• Mashup Score: 0
    ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177 - 2 year(s) ago

    ONTARIO, CANADA, and MUNICH, GERMANY , October 24, 2022 – An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), announced today the commencement of commercial production of lutetium-177.   The announcement was celebrated at ITM’s headquarters in Munich, Germany, along with representatives of the partnership…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      We announced today together with our international partners @Bruce_Power and Isogen the commencement of commercial production of lutetium-177 at the novel Isotope Production System (IPS) in Bruce Power’s Unit 7. Read full press release at: https://t.co/cZyLKKRVx7 https://t.co/lVQdGdkZtv

  • Mashup Score: 0
    ITM Multiplies Production Capacity for its n.c.a. Lutetium-177 - 2 year(s) ago

    Garching / Munich, October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production line for the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) at its production facility IAZ in Garching near Munich. The new production line was inspected and approved by the competent…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      Today we announced the successful completion of a new production line for the medical radioisotope n.c.a. lutetium-177 at ITM’s production facility IAZ in Garching near Munich. With this extension, we have multiplied our production capacity. Read more at: https://t.co/dembs0HIsr https://t.co/jG1qi3VgHh

  • Mashup Score: 0
    ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022 - 2 year(s) ago

    Garching / Munich, September 06, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second phase III clinical trial, COMPOSE, in advanced neuroendocrine tumors (GEP-NETs) will be presented at the upcoming ESMO Congress from September 9-13, 2022, in Paris. The start of patient treatment in…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      Design of our second phase 3 clinical trial, COMPOSE, with our lead radiopharmaceutical candidate, ITM-11, for the treatment of high grade #GEP-NETs to be presented at #ESMO2022 Congress from September 9-13 in Paris. For further details visit: https://t.co/kXCDoBBjbx https://t.co/t0RJHWi5Vb

  • Mashup Score: 0
    ITM Acquires a New Platform for the Development of Next-Generation Theranostics - 2 year(s) ago

    Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics  Garching / Munich, August 18, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it has signed an agreement to acquire Positron Precision GmbH, a company…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      The acquisition of Positron Precision GmbH further strengthens our position in radiodiagnostics and will add new therapeutic candidates to ITM’s robust #oncology pipeline. Full press release at: https://t.co/Lx5tQQ4Mf8 https://t.co/TQkXepZ7XF

  • Mashup Score: 0
    ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board - 2 year(s) ago

    Garching / Munich, July 22, 2022  – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board as Chief Business Officer (CBO) of the ITM Group. Dr. Marx joined ITM in 2008 and has since contributed significantly to the company’s growth and development across various product management…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      ITM today announces the appointment of Dr. Sebastian Marx as CBO. Dr. Marx will further strengthen the marketing focus in preparing the potential launch of radiopharmacutical lead candidate ITM-11 for treatment of GEP-NETs. Press release at: https://t.co/eAYDWDTqlU #oncology https://t.co/blYSBQXr51

  • Mashup Score: 0
    ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 - 2 year(s) ago

    ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive solid tumorsGarching / Munich, Germany, July 21, 2022 – ITM Isotope Technologies Munich SE (ITM),  a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      ITM announces supply our medical radioisotope, no-carrier-added Lutetium-177, to Y-mAbs Therapeutics, Inc. for the clinical development of their Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex. Read the full press release: https://t.co/XBwEC14mjD https://t.co/KU1mqwkmr5

  • Mashup Score: 0
    ITM Symposium on Actinium-225 Targeted Radionuclide Therapy at Theranostics World Congress - 2 year(s) ago

    The symposium titled, “Actinium-225 Targeted Radionuclide Therapy – Current Perspective and Future Outlooks” will take place on June 25, from 11:30 am to 12:55 pm CET. Participants can attend in person or join via live stream, which will be available on the TWC website ahead of the congress.The event will feature expert speakers, Prof. Matthias Eiber, Associate Professor, Clinic and Polyclinic…

    Source: itm-radiopharma.com
    Categories: Future of Medicine, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ITM_Radiopharma
      ITM_Radiopharma

      Meet us from today to June 26 at the 6th Theranostics World Congress (TWC) in Wiesbaden, Germany. Connect with us at our booth and join ITM’s lunch symposium on actinium-225 tomorrow from 11:30 am to 12:55 pm CET. More about our symposium at: https://t.co/p12WidOgSv https://t.co/FfD0tEI95g

Load More